DE3306128C2 - Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 - Google Patents
Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7Info
- Publication number
- DE3306128C2 DE3306128C2 DE19833306128 DE3306128A DE3306128C2 DE 3306128 C2 DE3306128 C2 DE 3306128C2 DE 19833306128 DE19833306128 DE 19833306128 DE 3306128 A DE3306128 A DE 3306128A DE 3306128 C2 DE3306128 C2 DE 3306128C2
- Authority
- DE
- Germany
- Prior art keywords
- drug
- octanedione
- ischemic
- tetramethyl
- blood flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 23
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 230000003257 anti-anginal effect Effects 0.000 abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 230000017531 blood circulation Effects 0.000 description 19
- 230000000302 ischemic effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 13
- 239000013543 active substance Substances 0.000 description 12
- 230000004872 arterial blood pressure Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- UERHIZBSLAGDLU-UHFFFAOYSA-N 3-(2,3,4,5,6,7,8,8a-octahydro-1h-pyrrolo[1,2-a]pyrazine-2,5-diium-2-yl)-1-(2-chlorophenothiazin-10-yl)propan-1-one;dichloride Chemical compound Cl.Cl.C1CN2CCCC2CN1CCC(=O)N1C2=CC=CC=C2SC2=CC=C(Cl)C=C21 UERHIZBSLAGDLU-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- -1 alcohol nitrates Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 229950009941 chloralose Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- MGJKQDOBUOMPEZ-UHFFFAOYSA-N N,N'-dimethylurea Chemical compound CNC(=O)NC MGJKQDOBUOMPEZ-UHFFFAOYSA-N 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000036584 pressor response Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HKDOIORVQFUBKO-UHFFFAOYSA-L trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C HKDOIORVQFUBKO-UHFFFAOYSA-L 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108010080213 vascular factor Proteins 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833306128 DE3306128C2 (de) | 1983-02-22 | 1983-02-22 | Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833306128 DE3306128C2 (de) | 1983-02-22 | 1983-02-22 | Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3306128A1 DE3306128A1 (de) | 1984-08-23 |
| DE3306128C2 true DE3306128C2 (de) | 1987-01-29 |
Family
ID=6191516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19833306128 Expired DE3306128C2 (de) | 1983-02-22 | 1983-02-22 | Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3306128C2 (pl) |
-
1983
- 1983-02-22 DE DE19833306128 patent/DE3306128C2/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3306128A1 (de) | 1984-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69833254T2 (de) | Microdosistherapie von gefässbedingten erscheinungen durch no-donoren | |
| DE69621756T2 (de) | Betahydroxybuttersäure oder Acetoessigsäure oder deren Salze oder Ester zur Verwendung zur Verbesserung der Gehirnfunktion | |
| DE3505359A1 (de) | Arzneimittel zur behandlung von akuter, myocardialer ischaemie | |
| DE3320583A1 (de) | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung | |
| DE2828658A1 (de) | Verfahren zur photometrischen bestimmung der untereinheit b der creatin- kinase und reagens hierfuer | |
| DE69627160T2 (de) | Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen | |
| EP0363671B1 (de) | Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung | |
| DE2854316C2 (pl) | ||
| DE3234537C2 (de) | Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen | |
| DE3306128C2 (de) | Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| EP1244454B1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
| DE2952590A1 (de) | Verwendung von pyridinderivaten zur behandlung von blutandrang verursachendem herzversagen | |
| EP0032564A1 (de) | Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest | |
| DE2728589B2 (de) | Verwendung von 2-(2,2-disubstituierten)-ÄthylimidazoIinen bei der Bekämpfung von Diabetes | |
| DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
| US4571403A (en) | Antianginal medicated compound | |
| EP1227811B1 (de) | Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten | |
| RU2295968C2 (ru) | Комбинированный препарат, обладающий седативным, спазмолитическим и противоаллергическим действием | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| EP0479874B1 (de) | Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica | |
| DD283931A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen | |
| DE60016038T2 (de) | Neue verwendung von levosimendan | |
| EP1474134B1 (de) | Kombinationspräparat des natrium-wasserstoff-austausch-inhibitors cariporide mit ramipril zur verhinderung bzw zur hemmung der herzinsuffizienz | |
| EP0276369A2 (de) | Verwendung von Anipamil als Artereosklerosemittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |